ClinicalTrials.gg

Program

Phentolamine

Also written as “Phentolamine Ophthalmic Solution 0.75%”, “Phentolamine Mesylate Ophthalmic Solution 1%” and “Phentolamine Mesylate (NV-101)”.

Its studies are mostly in Mydriasis · Hypesthesia · Presbyopia · Vitamin A Deficiency · Glaucoma, Open-Angle, led by 3 companies.

Furthest: phase 4, since Nov 2, 202018 company-led studies, 1 open or runningNext primary completion: Aug 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Opus Genetics131 open or runningphase 3since Nov 2, 2020May 18, 2012Aug 2027phase 3 · NCT07140783
Novalar Pharmaceuticals40 open or runningphase 3since Mar 30, 2006Sep 8, 2005none ahead
Novocol Pharmaceutical of Canada10 open or runningphase 4since Nov 11, 2011Nov 11, 2011none ahead

Also a collaborator on its studies: Viatris.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 3 studies since Sep 8, 2005.

  1. Mar 30, 2006Phase 2 study in HypesthesiaNovalar Pharmaceuticals · NCT00309322 · 150 enrolled · United States
  2. Nov 11, 2011Novocol Pharmaceutical of Canada's first study: phase 4 study in Dental AnesthesiaNew to Novocol Pharmaceutical of CanadaNovocol Pharmaceutical of Canada · NCT01474382 · 150 enrolled · United States
  3. May 18, 2012Opus Genetics's first study: phase 2 study in Night Vision ComplaintsNew to Opus GeneticsOpus Genetics · NCT01703559 · 60 enrolled · United States
  4. May 21, 2019Phase 2 study in Glaucoma, Open-AngleOpus Genetics · NCT03960866 · 39 enrolled · United States
  5. Jun 28, 2019Phase 2 study in Decrease in Night VisionOpus Genetics · NCT04004507 · 24 enrolled · United States
  6. Jul 11, 2019Phase 2 study in MydriasisOpus Genetics · NCT04024891 · 32 enrolled · United States
  7. Nov 2, 20202 phase 3 studiesOpus Genetics · NCT04620213, NCT04638660
  8. Dec 15, 2020Phase 2 study in PresbyopiaOpus Genetics · NCT04675151 · 150 enrolled · United States
  9. Nov 16, 2021Phase 3 study in MydriasisOpus Genetics · NCT05134974 · 368 enrolled · United States
  10. Dec 16, 2021Phase 3 study in MydriasisOpus Genetics · NCT05223478 · 23 enrolled · United States
  11. Dec 2, 2022Phase 3 study in PresbyopiaOpus Genetics · NCT05646719 · 333 enrolled · United States
  12. Apr 1, 2024Phase 3 study in Vitamin A DeficiencyOpus Genetics · NCT06349759 · 200 enrolled · United States
  13. Aug 5, 2024Phase 3 study in PresbyopiaOpus Genetics · NCT06542497 · 569 enrolled · United States
  14. Aug 22, 2025Phase 3 study in Vitamin A DeficiencyOpus Genetics · NCT07140783 · 580 planned · United States

Ahead

  1. Aug 2027Primary completion: phase 3 study in Vitamin A DeficiencyOpus Genetics · NCT07140783

TargetBeta

“Adrenergic receptor alpha antagonist”ChEMBL 37, by rule

Other programs on the same 6 targets

ProgramCompanyFurthest phaseStudies
OxymetazolineruleAbbViephase 420
Epinephrinerulenasus-pharmaphase 417

Studies

All 18 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07140783Vitamin A Deficiency · United States3RecruitingOpus GeneticsAug 2027580
NCT06542497Presbyopia · United States3CompletedOpus GeneticsApr 3, 2025569
NCT06349759Vitamin A Deficiency · United States3CompletedOpus GeneticsApr 17, 2025200
NCT05646719Presbyopia · United States3CompletedOpus GeneticsOct 11, 2023333
NCT05223478Mydriasis · United States3CompletedOpus GeneticsApr 18, 202223
NCT05134974Mydriasis · United States3CompletedOpus GeneticsMar 18, 2022368
NCT04675151Presbyopia · United States2CompletedOpus GeneticsMay 17, 2021150
NCT04638660Dim Light Vision Disturbances · United States3CompletedOpus GeneticsMay 19, 2022144
NCT04620213Mydriasis · United States3CompletedOpus GeneticsDec 23, 2020185
NCT04024891Mydriasis · United States2CompletedOpus GeneticsSep 17, 201932
NCT04004507Decrease in Night Vision · United States2CompletedOpus GeneticsOct 200724
NCT03960866Glaucoma, Open-Angle · United States2CompletedOpus GeneticsSep 11, 201939
NCT01703559Night Vision Complaints · United States2CompletedOpus GeneticsApr 16, 201260
NCT01474382Dental Anesthesia · United States4CompletedNovocol Pharmaceutical of CanadaAug 2014150
NCT00309361Hypesthesia · United States3CompletedNovalar Pharmaceuticals240
NCT00309335Hypesthesia · United States3CompletedNovalar Pharmaceuticals240
NCT00309322Hypesthesia · United States2CompletedNovalar Pharmaceuticals150
NCT00154167Hypesthesia · United States2CompletedNovalar Pharmaceuticals122

How it is read

Names in the registry

  • “Phentolamine Ophthalmic Solution 0.75%”, 5 entries
  • “Phentolamine Mesylate Ophthalmic Solution 1%”, 3 entries
  • “Phentolamine Mesylate (NV-101)”, 3 entries
  • “Phentolamine Opthalmic Solution 0.75%”, 1 entry
  • “Phentolamine Mesylate Ophthalmic Solution 1.0%”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.